Meropenem
Meropenem is an intravenous (IV) penem antibiotic used to treat complicated skin infections, complicated infections inside the abdomen, and bacterial meningitis in children 3 months and older.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 23 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Meropenem (Merrem) is a strong IV carbapenem antibiotic that kills bacteria by attacking their cell walls. It has been in use since about 1996, is available as a generic, and treats complicated skin and abdominal infections and, in children 3 months and older, bacterial meningitis, usually when an infection is serious or resistant. Most people tolerate it well, and diarrhea, nausea, headache or a sore IV site are what they usually notice. The biggest risk is a serious allergic reaction, so mention any penicillin allergy, and report a severe rash, seizures or severe diarrhea right away. Kidney problems, past seizures and valproic acid use all raise seizure risk, so flag them too.
Clinical pearls
- Probenecid, a gout medicine, raises meropenem blood levels, so the two are not recommended together.
- Your kidney function sets the dose, so expect blood tests and dose adjustments, especially if you are older.
- Watery diarrhea from C. difficile, a gut infection, can start more than two months after the last dose, so report it.
- Muscle pain or weakness with dark urine can signal muscle breakdown, so report it right away.
Patient information guide A plain-language walkthrough of Meropenem, written from its FDA label.
What Meropenem is used for
▾
Meropenem is an IV antibiotic approved for these infections:
- Complicated skin and skin structure infections (adults and children 3 months and older only)
- Complicated intra-abdominal infections, including complicated appendicitis and peritonitis (adults and children)
- Bacterial meningitis (children 3 months and older only), including bacteria in the blood that occur with it
How Meropenem works
▾
Meropenem is a penem antibacterial that fights infection-causing bacteria.
Its effect is best linked to how much of each dosing interval the free drug level in your blood stays above the amount needed to stop the bacteria. This is why it is given on a regular schedule.
Meropenem dosage
▾
Meropenem is given through a vein by a healthcare professional, so food does not matter and there are no missed doses to make up at home.
- It is usually given every 8 hours as an infusion over about 15 to 30 minutes.
- Some doses may be given as a quick push over 3 to 5 minutes.
- Adults with reduced kidney function get lower or less frequent doses.
- Children's doses are based on weight, age and type of infection.
Follow your prescriber and the label.
Dosing details from the FDA-approved label
From the Meropenem prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Complicated skin and skin structure infections (cSSSI), adult patients
- 500 mg every 8 hours by intravenous infusion over 15 to 30 minutes
- For infections caused by Pseudomonas aeruginosa, 1 gram every 8 hours
- Dosage reduced in renal impairment (creatinine clearance 50 mL/min or less)
- Intra-abdominal infections, adult patients
- 1 gram every 8 hours by intravenous infusion over 15 minutes to 30 minutes
- Doses of 1 gram may also be given as intravenous bolus injection (5 mL to 20 mL) over 3 minutes to 5 minutes
- Creatinine clearance 26 to 50 mL/min: recommended dose every 12 hours; 10 to 25: one-half recommended dose every 12 hours; less than 10: one-half recommended dose every 24 hours
- Pediatric patients 3 months of age and older, complicated skin and skin structure infections
- 10 mg/kg every 8 hours
- For P. aeruginosa, 20 mg/kg (or 1 gram for patients weighing over 50 kg) every 8 hours
- Maximum: 500 mg every 8 hours
- No experience in pediatric patients with renal impairment
- Pediatric patients 3 months of age and older, intra-abdominal infections
- 20 mg/kg every 8 hours, by infusion over approximately 15 to 30 minutes or bolus over approximately 3 to 5 minutes
- Maximum: 1 gram every 8 hours
- No experience in pediatric patients with renal impairment
- Pediatric patients 3 months of age and older, meningitis
- 40 mg/kg every 8 hours
- Maximum: 2 grams every 8 hours
- Limited safety data for 40 mg/kg bolus dose
- Infants less than 32 weeks GA and PNA less than 2 weeks, complicated intra-abdominal infections
- 20 mg/kg every 12 hours, intravenous infusion over 30 minutes
- No experience in pediatric patients with renal impairment
- Infants less than 32 weeks GA and PNA 2 weeks and older, complicated intra-abdominal infections
- 20 mg/kg every 8 hours, intravenous infusion over 30 minutes
- Infants 32 weeks and older GA and PNA less than 2 weeks, complicated intra-abdominal infections
- 20 mg/kg every 8 hours, intravenous infusion over 30 minutes
- Infants 32 weeks and older GA and PNA 2 weeks and older, complicated intra-abdominal infections
- 30 mg/kg every 8 hours, intravenous infusion over 30 minutes
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION 500 mg every 8 hours by intravenous infusion over 15 to 30 minutes for complicated skin and skin structure infections (cSSSI) for adult patients. When treating infections caused by Pseudomonas aeruginosa , a dose of 1 gram every 8 hours is recommended. (2.1) 1 gram every 8 hours by intravenous infusion over 15 minutes to 30 minutes for intra-abdominal infections for adult patients. (2.1) 1 gram every 8 hours by intravenous bolus injection (5 mL to 20 mL) over 3 minutes to 5 minutes for adult patients. (2.1) Dosage should be reduced in adult patients with renal impairment. (2.2) Recommended Meropenem for Injection (I.V.) Dosage Schedule for Adult Patients with Renal Impairment Creatinine Clearance (mL/min) Dose (dependent on type of infection) Dosing Interval Greater than 50 Recommended dose (500 mg cSSSI and 1 gram Intra-abdominal) Every 8 hours 26 to 50 Recommended dose Every 12 hours 10 to 25 One-half recommended dose Every 12 hours Less than 10 One-half recommended dose Every 24 hours Pediatric patients 3 months of age and older. Recommended Meropenem for Injection (I.V.) Dosage Schedule for Pediatric Patients 3 Months of Age and Older with Normal Renal Function (2.3) Type of Infection Dose (mg/kg) Up to a Maximum Dose Dosing Interval Complicated skin and skin structure* 10 500 mg Every 8 hours Intra-abdominal 20 1 gram Every 8 hours Meningitis 40 2 gram Every 8 hours - Intravenous infusion is to be given over approximately 15 minutes to 30 minutes. - Intravenous bolus injection (5 mL to 20 mL) is to be given over approximately 3 minutes to 5 minutes. - There is no experience in pediatric patients with renal impairment. *20 mg/kg (or 1 gram for pediatric patients weighing over 50 kg) every 8 hours is recommended when treating complicated skin and skin structure infections caused by P. aeruginosa (2.3) .
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Meropenem side effects
▾
Most people tolerate meropenem, but some side effects are common.
Common side effects
- Diarrhea
- Nausea and vomiting
- Headache
- Rash
- Constipation
- Itching
- Anemia (low red blood cells)
- Redness, swelling or pain at the injection site
- Irritation, redness, swelling or pain at the injection site
When to get medical help
- Signs of a severe allergic reaction, such as trouble breathing, swelling of the face or throat, or hives. Get emergency help.
- Severe skin reactions, such as blistering, peeling or a spreading painful rash, with fever or mouth sores.
- Seizures, tremors, muscle jerks, confusion or hallucinations.
- Muscle pain, tenderness or weakness, or dark urine (possible rhabdomyolysis, a muscle breakdown).
- Severe or watery diarrhea, which can happen during treatment or even more than two months after it ends.
- Unusual bleeding or bruising, especially if you have kidney problems.
Meropenem warnings and precautions
▾
- Serious allergic reactions can occur and may be fatal, including in people allergic to penicillin.
- Severe skin reactions such as Stevens-Johnson syndrome have been reported. Stop the drug and get help.
- Seizures are more likely with brain disorders, meningitis or poor kidney function.
- Rhabdomyolysis (muscle breakdown) has been reported.
- C. difficile diarrhea can range from mild to fatal colitis and may appear weeks after treatment.
- Low platelets have been seen in people with kidney problems.
- Long use can allow other, nonsusceptible germs to overgrow.
- Seizures, delirium or headaches may affect alertness, so avoid driving until you know how you react.
Meropenem interactions
▾
Two drug interactions matter most.
- Valproic acid or divalproex sodium: meropenem lowers their levels, which can cause breakthrough seizures. This is generally not recommended.
- Probenecid: it blocks the kidneys from clearing meropenem, raising its levels, so it is not recommended.
Interactions listed in the FDA-approved label
From the Meropenem prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Probenecid: Probenecid competes with meropenem for active tubular secretion, inhibiting its renal excretion and increasing plasma concentrations of meropenem. Co-administration is not recommended.
- Valproic acid or divalproex sodium: Co-administration of carbapenems, including meropenem, reduces valproic acid concentrations, which may drop below the therapeutic range and increase the risk of breakthrough seizures. Concomitant use is generally not recommended; consider antibacterial drugs other than carbapenems, or if meropenem is necessary, consider supplemental anti-convulsant therapy.
Read the label’s full interactions text
7 DRUG INTERACTIONS • Co-administration of meropenem for injection with probenecid inhibits renal excretion of meropenem and therefore Meropenem for Injection is not recommended ( 7.1 ) • The concomitant use of Meropenem for Injection and valproic acid or divalproex sodium is generally not recommended. Antibacterial drugs other than carbapenems should be considered to treat infections in patients whose seizures are well controlled on valproic acid or divalproex sodium. ( 5.4 , 7.2 ) 7.1 Probenecid Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Co-administration of probenecid with meropenem is not recommended. 7.2 Valproic Acid Case reports in the literature have shown that co-administration of carbapenems, including meropenem, to patients receiving valproic acid or divalproex sodium results in a reduction in valproic acid concentrations. The valproic acid concentrations may drop below the therapeutic range as a result of this interaction, therefore increasing the risk of breakthrough seizures. Although the mechanism of this interaction is unknown, data from in vitro and animal studies suggest that carbapenems may inhibit the hydrolysis of valproic acid’s glucuronide metabolite (VPA-g) back to valproic acid, thus decreasing the serum concentrations of valproic acid. If administration of meropenem for injection is necessary, then supplemental anti-convulsant therapy should be considered [ see Warnings and Precautions ( 5.4 ) ].
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Meropenem
▾
- Do not use it with a known allergy to meropenem, similar drugs, or a history of anaphylaxis to beta-lactams.
- Share any past reactions to penicillins, cephalosporins or other allergens.
- Tell your team about seizure history, brain disorders or meningitis.
- Kidney problems require a lower dose. Older adults may need extra care in dose selection and kidney monitoring.
- Pregnancy: human data are insufficient. Animal studies showed no fetal harm.
- Breastfeeding: meropenem has been reported in breast milk. Discuss the benefits and risks with your doctor.
- Children: approved from 3 months for skin infections and meningitis, and all ages for intra-abdominal infections.
Meropenem overdose
▾
Overdose is unlikely, but it can happen if large doses are given to people with reduced kidney function. Reported effects are generally mild and match the usual side effects, and they resolve when the drug is stopped or the dose lowered. Treatment is symptom-based, and meropenem can be removed by hemodialysis.
What Meropenem does in the body
▾
Meropenem works best when the free drug level in your blood stays above the amount needed to stop the infecting bacteria for as much of the dosing interval as possible. This was shown in animal and lab models.
How your body processes Meropenem
▾
Meropenem is given by vein, so it reaches the blood right away. It spreads into many tissues and fluids, with the highest levels about an hour after an infusion starts. Its half-life is about 1 hour with normal kidney function. Most of it leaves unchanged through the kidneys, and one inactive breakdown product is made. Kidney problems slow clearance, which is why doses are lowered.
How to store Meropenem
▾
stored at 20°–25°C (68°–77°F) .
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Meropenem: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Meropenem — the kind of thing our pharmacy team would talk through with you at the counter.
What is meropenem used for?
▾
How will I get it?
▾
What side effects should I expect?
▾
When should I call for help right away?
▾
Does it interact with my other medicines?
▾
Is it safe in pregnancy or while breastfeeding?
▾
Is Meropenem available over the counter?
▾
When was Meropenem first available?
▾
Who makes Meropenem?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Meropenem on HelloPharmacist
Meropenem forms and strengths (how it comes)
Meropenem is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Meropenem for injection is used for complicated skin and skin structure infections in adults and children 3 months and older.
- Meropenem for injection is used for complicated intra-abdominal infections in adults and children.
- Meropenem for injection is used for bacterial meningitis in children 3 months and older.
- Meropenem for injection is given by intravenous infusion over about 15 to 30 minutes.
- Meropenem for injection may also be given as an intravenous bolus injection over about 3 to 5 minutes.
- Meropenem for injection dosing is lowered for adults with reduced kidney function.
Show 1 more strength Show fewer strengths
Meropenem on the U.S. market: products, makers and brands
How Meropenem appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
17 companies list 43 Meropenem product records with the FDA, mostly as injection; the earliest marketing or approval year on record is 1996.
Also listed with the FDA, not a patient dose form: Powder (3) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Meropenem is used (Medicaid data)
A general measure of how commonly Meropenem is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Meropenem is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Meropenem prescribed? Of the 1,601 medications we measure, Meropenem ranks #732 by Medicaid prescriptions — more than 54% of them.
Utilization by Meropenem product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
meropenem 1000 MG Injection Most dispensed
Summed across the 15 of 43 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1722939
meropenem 500 MG Injection
Summed across the 12 of 43 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1722934
meropenem 2000 MG Injection
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2664894
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Meropenem, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 29 of 92 listed Meropenem NDCs with Medicaid activity.
Compare Meropenem products
A representative set of FDA-listed product records for Meropenem — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 500 mg/20 mL | Intravenous | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | Amneal Pharmaceuticals LLC | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Armas Pharmaceuticals Inc | ANDA | View NDC → |
| 1 g/20 mL | Intravenous | Armas Pharmaceuticals Inc | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | BluePoint Laboratories | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Brooks Steriscience Limited | ANDA | View NDC → |
| 1 g/20 mL | Intravenous | Brooks Steriscience Limited | ANDA | View NDC → |
| 2 g | Intravenous | Brooks Steriscience Limited | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Civica, Inc | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | Civica, Inc | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Civica, Inc. | ANDA | View NDC → |
| 1 g/20 mL | Intravenous | Civica, Inc. | ANDA | View NDC → |
| 500 mg | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 1 g | Intravenous | Eugia US LLC | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 1 g/20 mL | Intravenous | Fresenius Kabi USA, LLC | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Gland Pharma Limited | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | Gland Pharma Limited | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 1 g/20 mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 500 mg/10 mL | Intravenous | Hospira, Inc. × 2 listings | ANDA | View NDC → |
| 1 g/20 mL | Intravenous | Hospira, Inc. × 2 listings | ANDA | View NDC → |
| 2 g | Intravenous | Mylan Institutional LLC | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Qilu Antibiotics Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | Qilu Antibiotics Pharmaceutical Co., Ltd. | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | Sagent Pharmaceuticals | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Sandoz Inc | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | Sandoz Inc | ANDA | View NDC → |
| 500 mg/20 mL | Intravenous | Savior Lifetec Corporation | ANDA | View NDC → |
| 1 g/30 mL | Intravenous | Savior Lifetec Corporation | ANDA | View NDC → |
| 500 mg | Intravenous | WG Critical Care, LLC × 2 listings | ANDA | View NDC → |
| 1 g | Intravenous | WG Critical Care, LLC × 2 listings | ANDA | View NDC → |
| 2 g | Intravenous | WG Critical Care, LLC | NDA | View NDC → |
| 500 mg | Intravenous | Xellia Pharmaceuticals USA LLC | ANDA | View NDC → |
| 1 g | Intravenous | Xellia Pharmaceuticals USA LLC | ANDA | View NDC → |
Showing 43 of 43 products — FDA National Drug Code Directory. See every product, package size and price: browse all 43 Meropenem NDCs →
Meropenem side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Meropenem — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Meropenem in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Meropenem FDA approval history
How Meropenem went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Meropenem recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Meropenem recalls since July 2021.
✅No Meropenem recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 29561 1 dose form · 3 strengths
-
Dose form (SCDF) Injection RxCUI 1722933In current FDA listings
Look up RxCUI 29561 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Meropenem supply and shortage status
Whether Meropenem is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
💵 What Meropenem costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Injection, Powder, For Solution · Intravenous | 1 g | $4.69 each | NDC details & price history |
| Injection · Intravenous | 1 g/30 mL | $4.69 each | NDC details & price history |
| Injection · Intravenous | 1 g/20 mL | $4.69 each | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Who makes Meropenem: manufacturers and labelers
17 companies list Meropenem products with the FDA. By number of product records, the largest are WG Critical Care, LLC, Civica, Inc, Hikma Pharmaceuticals USA Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Meropenem drug class (RxNorm)
Meropenem belongs to the Penem Antibacterial class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Meropenem page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. WG Critical Care, LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →